Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.

Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y.

Urol Oncol. 2019 Dec 4. pii: S1078-1439(19)30459-4. doi: 10.1016/j.urolonc.2019.11.004. [Epub ahead of print]

PMID:
31812633
2.

Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.

Lu Z, Williamson SR, Carskadon S, Arachchige PD, Dhamdhere G, Schultz DS, Stricker H, Peabody JO, Jeong W, Chitale DA, Bismar TA, Rogers CG, Menon M, Gupta NS, Palanisamy N.

Prostate. 2020 Jan;80(1):38-50. doi: 10.1002/pros.23914. Epub 2019 Oct 4.

PMID:
31584209
3.

Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.

Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2019 Aug 27. doi: 10.1038/s41391-019-0167-9. [Epub ahead of print]

PMID:
31455846
4.

Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.

Boufaied N, Takhar M, Nash C, Erho N, Bismar TA, Davicioni E, Thomson AA.

J Pathol. 2019 Dec;249(4):411-424. doi: 10.1002/path.5315. Epub 2019 Oct 16.

5.

Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.

Abou-Ouf H, Ghosh S, Box A, Palanisamy N, Bismar TA.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1751-1759. doi: 10.1007/s00432-019-02933-z. Epub 2019 May 25.

PMID:
31129769
6.

Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.

Alshalalfa M, Liu Y, Wyatt AW, Gibb EA, Tsai HK, Erho N, Lehrer J, Takhar M, Ramnarine VR, Collins CC, Den RB, Schaeffer EM, Davicioni E, Lotan TL, Bismar TA.

Int J Cancer. 2019 Dec 15;145(12):3453-3461. doi: 10.1002/ijc.32430. Epub 2019 Jun 10.

7.

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18.

8.

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, Davis JW, Mohler JL, Trock BJ, Klein EA, Tosoian JJ, Hyndman ME, Bismar TA.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):399-405. doi: 10.1038/s41391-018-0101-6. Epub 2018 Dec 12.

9.

Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.

10.

Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.

Bismar TA, Hegazy S, Feng Z, Yu D, Donnelly B, Palanisamy N, Trock BJ.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2117-2125. doi: 10.1007/s00432-018-2730-5. Epub 2018 Aug 12.

PMID:
30101374
11.

Quantitative in vivo whole genome motility screen reveals novel therapeutic targets to block cancer metastasis.

Stoletov K, Willetts L, Paproski RJ, Bond DJ, Raha S, Jovel J, Adam B, Robertson AE, Wong F, Woolner E, Sosnowski DL, Bismar TA, Wong GK, Zijlstra A, Lewis JD.

Nat Commun. 2018 Jun 14;9(1):2343. doi: 10.1038/s41467-018-04743-2.

12.

Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.

Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA.

J Cancer Res Clin Oncol. 2018 May;144(5):883-891. doi: 10.1007/s00432-018-2615-7. Epub 2018 Mar 6.

PMID:
29511883
13.

Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity.

Trpkov K, Abou-Ouf H, Hes O, Lopez JI, Nesi G, Comperat E, Sibony M, Osunkoya AO, Zhou M, Gokden N, Leroy X, Berney DM, Werneck Cunha I, Musto ML, Athanazio DA, Yilmaz A, Donnelly B, Hyndman E, Gill AJ, McKenney JK, Bismar TA.

Am J Surg Pathol. 2017 Oct;41(10):1299-1308. doi: 10.1097/PAS.0000000000000838.

PMID:
28786877
14.

ING3 promotes prostate cancer growth by activating the androgen receptor.

Nabbi A, McClurg UL, Thalappilly S, Almami A, Mobahat M, Bismar TA, Binda O, Riabowol KT.

BMC Med. 2017 May 16;15(1):103. doi: 10.1186/s12916-017-0854-0.

15.

Tubulovillous Adenoma in the Bladder in a Dual Pancreas-Kidney Transplant Patient.

Remondini T, Van Zyl S, Bismar TA, Yilmaz S, Hyndman ME.

J Endourol Case Rep. 2017 Feb 1;3(1):17-20. doi: 10.1089/cren.2016.0139. eCollection 2017.

16.

Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2.

Saad A, Bijian K, Qiu D, da Silva SD, Marques M, Chang CH, Nassour H, Ramotar D, Damaraju S, Mackey J, Bismar T, Witcher M, Alaoui-Jamali MA.

Sci Rep. 2016 Nov 7;6:36699. doi: 10.1038/srep36699.

17.

High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Box A, Alshalalfa M, Hegazy SA, Donnelly B, Bismar TA.

Tumour Biol. 2016 Sep;37(9):12287-12299. Epub 2016 Jun 7.

PMID:
27271990
18.

SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.

Huang KC, Evans A, Donnelly B, Bismar TA.

Pathol Oncol Res. 2017 Apr;23(2):399-407. doi: 10.1007/s12253-016-0119-9. Epub 2016 Oct 13.

PMID:
27738792
19.

Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.

Wang T, Abou-Ouf H, Hegazy SA, Alshalalfa M, Stoletov K, Lewis J, Donnelly B, Bismar TA.

J Mol Med (Berl). 2016 Dec;94(12):1411-1422. doi: 10.1007/s00109-016-1458-4. Epub 2016 Aug 18.

PMID:
27534968
20.

microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.

Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA.

Mol Biol Rep. 2016 Apr;43(4):229-40. doi: 10.1007/s11033-016-3948-4. Epub 2016 Feb 23.

PMID:
26907180
21.

ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.

Almami A, Hegazy SA, Nabbi A, Alshalalfa M, Salman A, Abou-Ouf H, Riabowol K, Bismar TA.

Tumour Biol. 2016 Jul;37(7):9731-8. doi: 10.1007/s13277-016-4802-y. Epub 2016 Jan 23.

PMID:
26803516
22.

Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer.

Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH, Aziz T, Bismar TA, Wei F, Wong N, De Melo J, Cutz JC, Major P, Wood G, Peng H, Tang D.

Cancer Res. 2016 Mar 15;76(6):1603-14. doi: 10.1158/0008-5472.CAN-15-1898. Epub 2016 Jan 21.

23.

SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.

Huang KC, Bégin LR, Palanisamy N, Donnelly B, Bismar TA.

Urol Oncol. 2016 May;34(5):235.e1-10. doi: 10.1016/j.urolonc.2015.11.015. Epub 2015 Dec 22.

PMID:
26725250
24.

ERG expression in prostate cancer: biological relevance and clinical implication.

Abou-Ouf H, Zhao L, Bismar TA.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1781-93. doi: 10.1007/s00432-015-2096-x. Epub 2015 Dec 28. Review.

PMID:
26711283
25.

ING3 protein expression profiling in normal human tissues suggest its role in cellular growth and self-renewal.

Nabbi A, Almami A, Thakur S, Suzuki K, Boland D, Bismar TA, Riabowol K.

Eur J Cell Biol. 2015 May;94(5):214-22. doi: 10.1016/j.ejcb.2015.03.002. Epub 2015 Mar 14.

PMID:
25819753
26.

ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications.

Lee SL, Yu D, Wang C, Saba R, Liu S, Trpkov K, Donnelly B, Bismar TA.

Appl Immunohistochem Mol Morphol. 2015 Aug;23(7):499-505. doi: 10.1097/PAI.0000000000000119.

PMID:
25517865
27.

The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.

Huang KC, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA.

Cancer Biol Ther. 2014 Sep;15(9):1120-8. doi: 10.4161/cbt.29689. Epub 2014 Jun 27.

28.

ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Huang KC, Dolph M, Donnelly B, Bismar TA.

Clin Transl Oncol. 2014 Nov;16(11):973-9. doi: 10.1007/s12094-014-1182-x. Epub 2014 May 6.

PMID:
24796295
29.

Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.

Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA.

J Hematol Oncol. 2014 Mar 7;7:21. doi: 10.1186/1756-8722-7-21.

30.

Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia.

Luchman HA, Villemaire ML, Bismar TA, Carlson BA, Jirik FR.

Am J Pathol. 2014 Mar;184(3):871-7. doi: 10.1016/j.ajpath.2013.11.025. Epub 2014 Jan 18.

31.

The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting.

Xu B, Teng LH, Silva SD, Bijian K, Al Bashir S, Jie S, Dolph M, Alaoui-Jamali MA, Bismar TA.

Cancer Med. 2014 Feb;3(1):14-24. doi: 10.1002/cam4.168. Epub 2013 Dec 18.

32.

Coordinate microRNA-mediated regulation of protein complexes in prostate cancer.

Alshalalfa M, Bader GD, Bismar TA, Alhajj R.

PLoS One. 2013 Dec 31;8(12):e84261. doi: 10.1371/journal.pone.0084261. eCollection 2013.

33.

Urinary bladder melanosis associated with urothelial dysplasia and invasive urothelial carcinoma: a report of two cases.

Patel P, Gotto G, Kavanagh A, Al Bashir S, Bismar TA, Trpkov K.

Anal Quant Cytopathol Histpathol. 2013 Oct;35(5):294-300.

PMID:
24282911
34.

Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells.

Chukkapalli S, Amessou M, Dilly AK, Dekhil H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA, Neill D, Azoulay L, Batist G, Kandouz M.

Exp Cell Res. 2014 Jan 15;320(2):233-46. doi: 10.1016/j.yexcr.2013.10.022. Epub 2013 Nov 6.

PMID:
24211352
35.

ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer.

Teng LH, Wang C, Dolph M, Donnelly B, Bismar TA.

ISRN Urol. 2013 Aug 19;2013:786545. doi: 10.1155/2013/786545. eCollection 2013.

36.

Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.

Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A, Al-Mami A, Liu S, Dolph M, Mucci LA, Alhajj R.

BJU Int. 2014 Feb;113(2):309-19. doi: 10.1111/bju.12262. Epub 2013 Sep 5.

37.

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.

38.

TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.

Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG.

Clin Cancer Res. 2013 Sep 15;19(18):5202-9. doi: 10.1158/1078-0432.CCR-13-1049. Epub 2013 Aug 5.

39.

ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.

Teng LH, Wang C, Bégin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA.

Urology. 2013 Aug;82(2):394-9. doi: 10.1016/j.urology.2013.03.029. Epub 2013 Jun 6.

PMID:
23746715
40.

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, Rubin MA.

Neoplasia. 2013 Jan;15(1):1-10.

41.

Protein network-based Lasso regression model for the construction of disease-miRNA functional interactions.

Qabaja A, Alshalalfa M, Bismar TA, Alhajj R.

EURASIP J Bioinform Syst Biol. 2013 Jan 22;2013(1):3. doi: 10.1186/1687-4153-2013-3.

42.

Familial prostate cancer: the damage done and lessons learnt.

Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.

Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.

43.

Use of immunohistochemistry in routine workup of prostate needle biopsies: a tertiary academic institution experience.

Watson K, Wang C, Yilmaz A, Bismar TA, Trpkov K.

Arch Pathol Lab Med. 2013 Apr;137(4):541-5. doi: 10.5858/arpa.2012-0145-OA. Epub 2012 Dec 28.

PMID:
23273390
44.

Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks.

Alshalalfa M, Bismar TA, Alhajj R.

Adv Bioinformatics. 2012;2012:373506. doi: 10.1155/2012/373506. Epub 2012 Jun 28.

45.

ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.

Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B.

Eur J Cancer. 2012 Mar;48(4):538-46. doi: 10.1016/j.ejca.2012.01.001. Epub 2012 Feb 1.

PMID:
22300588
46.

Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene.

Calderon MR, Verway M, An BS, DiFeo A, Bismar TA, Ann DK, Martignetti JA, Shalom-Barak T, White JH.

J Biol Chem. 2012 Mar 16;287(12):8662-74. doi: 10.1074/jbc.M111.311605. Epub 2012 Jan 25.

47.

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.

Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA.

Histopathology. 2012 Mar;60(4):645-52. doi: 10.1111/j.1365-2559.2011.04116.x. Epub 2012 Jan 19.

PMID:
22260502
48.

Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.

Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W.

Am J Pathol. 2012 Mar;180(3):895-903. doi: 10.1016/j.ajpath.2011.11.030. Epub 2012 Jan 11.

49.

PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.

Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG.

Clin Cancer Res. 2012 Feb 15;18(4):1015-27. doi: 10.1158/1078-0432.CCR-11-2189. Epub 2011 Nov 23. Erratum in: Clin Cancer Res. 2012 May 1;18(9):2720.

50.

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.

Yoshimoto M, Ludkovski O, DeGrace D, Williams JL, Evans A, Sircar K, Bismar TA, Nuin P, Squire JA.

Genes Chromosomes Cancer. 2012 Feb;51(2):149-60. doi: 10.1002/gcc.20939. Epub 2011 Nov 1.

PMID:
22045666

Supplemental Content

Loading ...
Support Center